SCHEMBL6788362

SCHEMBL6788362

CCOC(=O)c1cc(NC(=O)OC(C)(C)C)ccc1NC(=O)/C=C(/C)c1ccc2ccccc2c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TERT O14746 5/20 0.53
LMNA P02545 1/20 0.47
KAT6A Q92794 1/20 0.42
ALDH1A1 P00352 3/20 0.39
ELANE P08246 1/20 0.39
PRTN3 P24158 1/20 0.39
CA12 O43570 1/20 0.39
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39
CA9 Q16790 1/20 0.39
CYP1A2 P05177 2/20 0.38
CYP2C19 P33261 2/20 0.38
KDM4E B2RXH2 1/20 0.38
HPGD P15428 2/20 0.38
MAPK1 P28482 2/20 0.38
CNR2 P34972 1/20 0.38
KMT2A Q03164 1/20 0.37
CYP2D6 P10635 1/20 0.37
CYP2C9 P11712 1/20 0.37
ALOX15 P16050 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6787182 0.89 TERT (0.66) TERTKAT6AALDH1A1KDM4EGABRB1
SCHEMBL6783765 0.86 TERT (0.59) TERTLMNAALDH1A1CA12CA1
SCHEMBL6791830 0.86 TERT (0.56) TERTLMNAALDH1A1CA12CA1
SCHEMBL6788177 0.84 TERT (0.55) TERTLMNAALDH1A1CA12CA1
SCHEMBL6790905 0.83 TERT (0.51) TERTLMNAALDH1A1ELANEPRTN3
SCHEMBL6786590 0.83 TERT (0.55) TERTLMNAALDH1A1CA12CA1
SCHEMBL6784598 0.82 TERT (0.53) TERTLMNAALDH1A1CA12CA1
SCHEMBL6784867 0.81 TERT (0.55) TERTLMNAALDH1A1CYP1A2CYP2C19
SCHEMBL6791907 0.81 TERT (0.50) TERTLMNAALDH1A1KDM4EKMT2A
SCHEMBL6784141 0.81 TERT (0.58) TERTLMNAALDH1A1CYP1A2CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6727250-B2 ADMINISTERING COMPOUNDS SUCH AS TRANS-3-(NAPHTH-2-YL)-BUT-2-ENOIC ACID-N-(2-CARBOXY-PHENYL)-AMIDE OR LIKE FOR THERAPY OF CONDITIONS ASSOCIATED WITH INCREASED TELOMERASE ACTIVITY, E.G. TUMOUR DISEASES BOEHRINGER INGELHEIM PHARMA KG (DE) 2004-04-27 US disclosed
US-20020099089-A1 Carboxylic acid amides, pharmaceutical compositions containing these compounds, their use and preparation BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2002-07-25 US disclosed
US-6362210-B1 ANTITUMOR, ANTICANCER AGENT BOEHRINGER INGELHEIM PHARMA KG (DE) 2002-03-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020099089-A1 Carboxylic acid amides, pharmaceutical compositions containing these compounds, their use and preparation TERT, NAT1, POT1 TERT 1/4885LMNA 169/4885KAT6A 315/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.